Imperial College Healthcare NHS Trust has enrolled the first United Kingdom (UK) patients who have received an experimental messenger RNA (mRNA) therapy — a type of immunotherapy treatment called mRNA-4359 — in its Phase I/II clinical trial.
FDA approved and implemented updated warning labels for all opioid prescriptions.
A new study showed patients with confirmed Ebola virus disease were half as likely to die if they were vaccinated against the virus than if they were not.
FDA approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with unresectable melanoma or metastatic melanoma that previously has been treated with other therapies.
FDA has approved Alvotech’s Simlandi (adalimumab-ryvk) as the third interchangeable Humira biosimilar.
CMS finalized policies to support primary care, advance health equity, assist family caregivers and expand access to behavioral and certain oral healthcare.
University of Arizona Health Sciences researchers have received a $13.1 million grant from the National Institute on Aging to continue studies aimed at rejuvenating the immune system of older people to improve health throughout the lifespan.
The U.S. Department of Health and Human Services and the General Services Administration have announced new guidance recommending that all federal facilities across the nation include overdose reversal medications in their safety stations on site.
Octapharma USA's wilate, von Willebrand factor (VWF)/coagulation factor VIII complex (human) lyophilized power for solution for intravenous injection, has been given expanded approval by the U.S. Food and Drug Administration (FDA) for routine prophylaxis to reduce the frequency of bleeding episodes in adults and children aged 6 and older with any type of von Willebrand disease (VWD).
In a study, researchers found that fSCIG 10% was more effective in preventing CIDP relapse than placebo, supporting its potential use as maintenance CIDP treatment.
A team of Australian investigators conducted a retrospective cohort study to determine whether there is a significant benefit in more severely affected cases regularly infused with albumin.
An international early-phase clinical trial has found a "two-for-one" cancer immunotherapy, tebotelimab, is potentially more effective and at least as safe as standard immunotherapies.
